Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …

This paper provides a brief review of the history, proposed pharmacological mechanisms,
safety issues, and clinical applications of the medicine 3, 4 …

Novel psychoactive substances are newly used designer drugs (" internet drugs"," research
chemicals"," legal highs") potentially posing similar health risks to classic illicit substances …

Background: Lysergic acid diethylamide (LSD) and 3, 4-methylenedioxymethamphetamine
(MDMA) were used in psychotherapy in the 1960s–1980s, and are currently being re …

Abstract Rationale & objectives±3, 4-Methylenedioxymethamphetamine (MDMA) and
psilocybin are currently moving through the US Food and Drug Administration's phased drug …

3, 4-Methylenedioxymethamphetamine (MDMA; ecstasy) is being investigated in MDMA-
assisted psychotherapy. The present study characterized the safety pharmacology of single …

Spontaneous Spiritual Awakenings (SSAs) are subjective experiences characterised by a
sudden sense of direct contact, union, or complete nondual merging (experience of …

Abstract Users of±3, 4-methylenedioxymethamphetamine (MDMA;'ecstasy') report prosocial
effects such as sociability and empathy. Supporting these apparently unique social effects …

Abstract Background The compound 3, 4-methylenedioxymethamphetamine (MDMA) is a
potent monoamine releaser that produces an acute euphoria in most individuals. Methods In …

In this paper, we present the development of the Altered States Database (ASDB), an open-
science project based on a systematic literature review. The ASDB contains psychometric …